Back to search

Peptide record

TPDB10832

P Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard
26 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10832
P
Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept CAFPdb HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 26-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KWKSFLKTFKSAKKTVLHTALKAISS
Physicochemical Analysis
C139H230N36O34
RNDCEQGMPY
K
2949.58
11.29
8
0
11
+7
2.29
-0.215
82.69
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
186.47
7
Residue Composition
number
3
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
1
H
1
I
3
L
7
K
0
M
2
F
0
P
4
S
3
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 3 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 1 L: 3 K: 7 M: 0 F: 2 P: 0 S: 4 T: 3 W: 1 Y: 0 V: 1
Chemical Descriptors
26
C139H230N36O34
2949.58
11.29
+7
2.29
-0.215
Free
L
Linear
Free
Anticancer
PeptideV13K
Evidence Records 37 records
Evidence 1 Activity

Activity

MIC
Antibacterial
2-4 µg/mL

Target

Escherichia coli ATCC 25922 or clinical strain

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
active against Gram- E. coli ATCC 25922 or clinical strain (MIC 2-4 ug/ml), P. aeruginosa ATCC 27853 or clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clin
Evidence 2 Activity

Activity

MIC
Antibacterial
8-16 µg/mL

Target

Pseudomonas aeruginosa ATCC 27853 or clinical

Source & Reference

dbAMP DRAMP

Other

active against Gram- E. coli ATCC 25922 or clinical strain (MIC 2-4 ug/ml), P. aeruginosa ATCC 27853 or clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRS
Evidence 3 Activity

Activity

MIC
Antibacterial
4-8 µg/mL

Target

Klebsiella pneumoniae ATCC 700603 or clinical

Source & Reference

dbAMP DRAMP

Other

r clinical strain (MIC 2-4 ug/ml), P. aeruginosa ATCC 27853 or clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4
Evidence 4 Activity

Activity

MIC
Antibacterial
64-128 µg/mL

Target

S. aeurus ATCC 25923 or MRSA

Source & Reference

dbAMP DRAMP

Other

r clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumon
Evidence 5 Activity

Activity

MIC
Antibacterial
4 µg/mL

Target

Staphylococcus epidermidis ATCC 12228

Source & Reference

dbAMP DRAMP

Other

00603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumoniae clinical isolate (MIC 8 ug/ml), alpha
Evidence 6 Activity

Activity

MIC
Antibacterial
8 µg/mL

Target

B. subtilis ATCC 6633

Source & Reference

dbAMP DRAMP

Other

S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumoniae clinical isolate (MIC 8 ug/ml), alpha or beta Hemolytic streptococcus (MIC
Evidence 7 Activity

Activity

MIC
Antibacterial
8 µg/mL

Target

S. pneumoniae clinical isolate

Source & Reference

dbAMP DRAMP

Other

128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumoniae clinical isolate (MIC 8 ug/ml), alpha or beta Hemolytic streptococcus (MIC 64 ug/ml).
Evidence 8 Activity

Activity

IC50
IC50=33 µMo/L
Anticancer
33 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 9 Activity

Activity

IC50
IC50=17.8 µMo/L
Anticancer
17.8 µM

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 10 Activity

Activity

IC50
IC50=15.8 µMo/L
Anticancer
15.8 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 11 Activity

Activity

IC50
IC50=11.1 µMo/L
Anticancer
11.1 µM

Target

Colorectal Cancer
SW-1116
Colon

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 12 Activity

Activity

IC50
IC50=25.2 µMo/L
Anticancer
25.2 µM

Target

Rhabdomyosarcoma Cancer
RD
Muscle

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 13 Activity

Activity

IC50
IC50=4.7 µMo/L
Anticancer
4.7 µM

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 14 Activity

Activity

IC50
IC50=11.5 µMo/L
Anticancer
11.5 µM

Target

Skin Cancer
B-16
Skin

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 15 Activity

Activity

IC50
IC50=10.4 µMo/L
Anticancer
10.4 µM

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 16 Activity

Activity

MIC
Antifungal
2-4 µg/mL

Target

Escherichia coli ATCC 25922 or clinical strain

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
active against Gram- E. coli ATCC 25922 or clinical strain (MIC 2-4 ug/ml), P. aeruginosa ATCC 27853 or clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clin
Evidence 17 Activity

Activity

MIC
Antifungal
8-16 µg/mL

Target

Pseudomonas aeruginosa ATCC 27853 or clinical

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

active against Gram- E. coli ATCC 25922 or clinical strain (MIC 2-4 ug/ml), P. aeruginosa ATCC 27853 or clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRS
Evidence 18 Activity

Activity

MIC
Antifungal
4-8 µg/mL

Target

Klebsiella pneumoniae ATCC 700603 or clinical

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

r clinical strain (MIC 2-4 ug/ml), P. aeruginosa ATCC 27853 or clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4
Evidence 19 Activity

Activity

MIC
Antifungal
64-128 µg/mL

Target

S. aeurus ATCC 25923 or MRSA

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

r clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumon
Evidence 20 Activity

Activity

MIC
Antifungal
4 µg/mL

Target

Staphylococcus epidermidis ATCC 12228

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

00603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumoniae clinical isolate (MIC 8 ug/ml), alpha
Evidence 21 Activity

Activity

MIC
Antifungal
8 µg/mL

Target

B. subtilis ATCC 6633

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumoniae clinical isolate (MIC 8 ug/ml), alpha or beta Hemolytic streptococcus (MIC
Evidence 22 Activity

Activity

MIC
Antifungal
8 µg/mL

Target

S. pneumoniae clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumoniae clinical isolate (MIC 8 ug/ml), alpha or beta Hemolytic streptococcus (MIC 64 ug/ml).
Evidence 23 Activity

Activity

MIC
Antiparasitic
2-4 µg/mL

Target

Escherichia coli ATCC 25922 or clinical strain

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
active against Gram- E. coli ATCC 25922 or clinical strain (MIC 2-4 ug/ml), P. aeruginosa ATCC 27853 or clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clin
Evidence 24 Activity

Activity

MIC
Antiparasitic
8-16 µg/mL

Target

Pseudomonas aeruginosa ATCC 27853 or clinical

Source & Reference

DRAMP

Other

active against Gram- E. coli ATCC 25922 or clinical strain (MIC 2-4 ug/ml), P. aeruginosa ATCC 27853 or clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRS
Evidence 25 Activity

Activity

MIC
Antiparasitic
4-8 µg/mL

Target

Klebsiella pneumoniae ATCC 700603 or clinical

Source & Reference

DRAMP

Other

r clinical strain (MIC 2-4 ug/ml), P. aeruginosa ATCC 27853 or clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4
Evidence 26 Activity

Activity

MIC
Antiparasitic
64-128 µg/mL

Target

S. aeurus ATCC 25923 or MRSA

Source & Reference

DRAMP

Other

r clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumon
Evidence 27 Activity

Activity

MIC
Antiparasitic
4 µg/mL

Target

Staphylococcus epidermidis ATCC 12228

Source & Reference

DRAMP

Other

00603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumoniae clinical isolate (MIC 8 ug/ml), alpha
Evidence 28 Activity

Activity

MIC
Antiparasitic
8 µg/mL

Target

B. subtilis ATCC 6633

Source & Reference

DRAMP

Other

S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumoniae clinical isolate (MIC 8 ug/ml), alpha or beta Hemolytic streptococcus (MIC
Evidence 29 Activity

Activity

MIC
Antiparasitic
8 µg/mL

Target

S. pneumoniae clinical isolate

Source & Reference

DRAMP

Other

128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumoniae clinical isolate (MIC 8 ug/ml), alpha or beta Hemolytic streptococcus (MIC 64 ug/ml).
Evidence 30 Activity

Activity

MHC
Hemolysis
250.0 µg/mL
[Ref.17158938]MHC=250.0 µg/ml against human red blood cells

Target

human red blood cells

Source & Reference

Hemolytik PD_Hemolysis
DRAMP4
J Biol Chem. 2005 Apr 1 280(13):12316-29.##Antimicrob Agents Chemother. 2007 Apr 51(4):1398-406.

Other

Source Activity Label Source Definition
Hemolysis
Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 31 Activity

Activity

MHC
Hemolysis
250.0 µg/mL
[Ref.15677462]MHC>250.0 µg/ml against human red blood cells

Target

human red blood cells

Source & Reference

Hemolytik PD_Hemolysis
DRAMP4
J Biol Chem. 2005 Apr 1 280(13):12316-29.
Evidence 32 Activity

Activity

0% Hemolysis
Toxicity
250.0 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 250.0 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evidence 33 Activity

Activity

28.3% Hemolysis
Toxicity
1000 µg/mL
Hemolytic Cytotoxic
28.3% Hemolysis | 1000 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Effects of single amino acid substitution on the biophysical properties and biological activities of an amphipathic ?-helical antibacterial peptide against Gram-negative bacteria. | Molecules | 2014
Evidence 34 Activity

Activity

MHC
Toxicity
250.0 µg/mL
Hemolytic
Hemolytic_activity: [Ref.17158938]MHC=250.0 µg/ml against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
J Biol Chem. 2005 Apr 1 280(13):12316-29.##Antimicrob Agents Chemother. 2007 Apr 51(4):1398-406.
Evidence 35 Activity

Activity

MHC
Toxicity
250.0 µg/mL
Hemolytic
Hemolytic_activity: [Ref.15677462]MHC>250.0 µg/ml against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
J Biol Chem. 2005 Apr 1 280(13):12316-29.
Evidence 36 Hemolysis

Activity

250.0 µg/mL
MHC
[Ref.17158938]MHC=250.0 µg/ml against human red blood cells
Hemolysis

Target

human red blood cells

Source & Reference

HemoPI PD_Hemolysis
J Biol Chem. 2005 Apr 1 280(13):12316-29.##Antimicrob Agents Chemother. 2007 Apr 51(4):1398-406.
DRAMP4
PD_Hemolysis
Evidence 37 Hemolysis

Activity

250.0 µg/mL
MHC
[Ref.15677462]MHC>250.0 µg/ml against human red blood cells
Hemolysis

Target

human red blood cells

Source & Reference

HemoPI PD_Hemolysis
J Biol Chem. 2005 Apr 1 280(13):12316-29.
DRAMP4
PD_Hemolysis